TY - JOUR
T1 - Temporal variability of the electromechanical window in long-QT syndrome and drug-induced QT prolongation
T2 - Value for enhanced arrhythmia-risk assessment
AU - Deissler, Peter M.
AU - Rahm, Ann Kathrin
AU - Berkovitch, Anat
AU - Müller, Mara Elena
AU - Sikking, Maurits
AU - Heymans, Stephane
AU - Langenberg, Benedikt
AU - Moersdorf, Maximilian
AU - Rieder, Marina
AU - Nimani, Saranda
AU - Odening, Katja E.
AU - Dichtl, Wolfgang
AU - Sabbag, Avi
AU - Volders, Paul G.A.
AU - Ter Bekke, Rachel M.A.
N1 - Funding Information:
P.D. was supported by the German Academic Scholarship Foundation and the German Research Foundation (Walter Benjamin Programme, 529532291). A.K.R. was supported by Heidelberg University Medical Faculty\u2019s Olympia Morata Grant. M.E.M. was funded by the Career Development Programme\u2014Short Term Fellowship\u2014of Heidelberg University, Faculty of Medicine. M.S. is supported by the Dutch Cardiovascular Alliance, an initiative with support of the Dutch Heart Foundation, and Stichting Hartedroom for financing the Double Dose program 2020-B005. S.H. receives personal fees for independent scientific advice on early development in the field of heart failure for AstraZeneca, Ribocure, and CSL Behring and receives research support from AstraZeneca and CSL Behring; the research leading to these results has received funding from the European Union Commission\u2019s Seventh Framework program under grant agreement number 305507 (HOMAGE). The support of IMI2-CARDIATEAM, from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement number 821508, is acknowledged. The Joint Undertaking receives support from the European Union\u2019s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations; The Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart Foundation, Dutch Cardiovascular Alliance Double Dosis, 2020-B005; and ZonMW-Metacor. M.R. was supported by a grant from the \u201CGottfried and Julia Bangerter-Rhyner-Stiftung\u201D Switzerland and the University Hospital of Bern, Inselspital (\u201CNachwuchsf\u00F6rderungs-Grant\u201D). K.E.O. received funding by a grant from the Swiss National Science Foundation (310030_197595) and a Bern Center of Precision Medicine Lighthouse grant. P.V. received grants from The Netherlands CardioVascular Research Initiative (CVON 2017-13 VIGILANCE and CVON 2018-30 PREDICT2), Den Haag, The Netherlands, and the Health Foundation Limburg, Maastricht. R.t.B. received grants from The Netherlands Organization for Scientific Research (Veni grant, 0915016181013) and the Health Foundation Limburg, Maastricht.
Funding Information:
P.D. was supported by the German Academic Scholarship Foundation and the German ResearchFoundation (Walter Benjamin Programme, 529532291).A.K.R. was supported by Heidelberg University Medical Faculty\u2019s Olympia Morata Grant. M.E.M. was funded by theCareer Development Programme\u2014Short Term Fellowship\u2014of Heidelberg University, Faculty of Medicine. M.S. is supported by the Dutch Cardiovascular Alliance, an initiativewith support of the Dutch Heart Foundation, and StichtingHartedroom for financing the Double Dose program 2020B005. S.H. receives personal fees for independent scientificadvice on early development in the field of heart failure forAstraZeneca, Ribocure, and CSL Behring and receivesresearch support from AstraZeneca and CSL Behring; theresearch leading to these results has received funding from theEuropean Union Commission\u2019s Seventh Framework programunder grant agreement number 305507 (HOMAGE). Thesupport of IMI2-CARDIATEAM, from the Innovative MedicinesInitiative 2 Joint Undertaking under grant agreement number821508, is acknowledged. The Joint Undertaking receivessupport from the European Union\u2019s Horizon 2020 researchand innovation program and the European Federation ofPharmaceutical Industries and Associations; The NetherlandsCardiovascular Research Initiative, an initiative with support ofthe Dutch Heart Foundation, Dutch Cardiovascular AllianceDouble Dosis, 2020-B005; and ZonMW-Metacor. M.R. wassupported by a grant from the \u201CGottfried and Julia BangerterRhyner-Stiftung\u201D Switzerland and the University Hospital ofBern, Inselspital (\u201CNachwuchsf\u20ACorderungs-Grant\u201D). K.E.O.received funding by a grant from the Swiss National ScienceFoundation (310030_197595) and a Bern Center of PrecisionMedicine Lighthouse grant. P.V. received grants from TheNetherlands CardioVascular Research Initiative (CVON 201713 VIGILANCE and CVON 2018-30 PREDICT2), Den Haag,The Netherlands, and the Health Foundation Limburg,Maastricht. R.t.B. received grants from The Netherlands OrganizationforScientificResearch(Venigrant,0915016181013) and the Health Foundation Limburg, Maastricht.
Publisher Copyright:
© 2026 Heart Rhythm Society.
PY - 2026/4/1
Y1 - 2026/4/1
N2 - Background Arrhythmia-risk assessment in congenital long-QT syndrome (LQTS) and drug-induced QT prolongation (diQTP) is primarily based on clinical, genetic, and electrical parameters. Electromechanical window (EMW) (aortic-valve closure time minus QT interval) assessment outperformed heart rate–corrected QT interval (QTc) as a predictor of symptomatic status in LQTS. Objective The study aimed to investigate the relationship between temporal QTc and EMW dynamics, and ventricular tachyarrhythmia (VT) timing in LQTS and diQTP. Methods 47 patients with LQTS/−VT, 18 patients with LQTS/+VT, 9 patients with diQTP/+VT, and 26 controls were included. QTc and EMW were obtained from standard 12-lead electrocardiograms and electrocardiogram-echocardiograms at 2 or 3 time points. Patients with +VT were included if EMW/QTc assessments were performed within 2 weeks before or after VT. Results In control subjects, EMW remained stably positive over time. In patients with LQTS/−VT, EMW was negative without significant variation. In patients with LQTS/+VT and diQTP/+VT, transient accentuations of EMW negativity were observed at the time point closest to VT (2 days [1–7] to arrhythmia), regardless of whether measured before or after VT. Temporary EMW negativity accentuation was driven by foreshortening of the mechanical systole despite concurrent QT prolongation. EMW recovery after VT was similar for patients with or without beta-blocker therapy. Multiple logistic regression analysis identified EMW negativity and EMW dynamics (ΔEMW) as independent predictors of imminent VT in LQTS. An EMW of −75 ms and a ΔEMW of −39 ms were optimal cutoffs to predict emergent arrhythmic deterioration in the LQTS cohort. Conclusion Temporary accentuation of EMW negativity is a marker of impending VT in patients with LQTS and diQTP.
AB - Background Arrhythmia-risk assessment in congenital long-QT syndrome (LQTS) and drug-induced QT prolongation (diQTP) is primarily based on clinical, genetic, and electrical parameters. Electromechanical window (EMW) (aortic-valve closure time minus QT interval) assessment outperformed heart rate–corrected QT interval (QTc) as a predictor of symptomatic status in LQTS. Objective The study aimed to investigate the relationship between temporal QTc and EMW dynamics, and ventricular tachyarrhythmia (VT) timing in LQTS and diQTP. Methods 47 patients with LQTS/−VT, 18 patients with LQTS/+VT, 9 patients with diQTP/+VT, and 26 controls were included. QTc and EMW were obtained from standard 12-lead electrocardiograms and electrocardiogram-echocardiograms at 2 or 3 time points. Patients with +VT were included if EMW/QTc assessments were performed within 2 weeks before or after VT. Results In control subjects, EMW remained stably positive over time. In patients with LQTS/−VT, EMW was negative without significant variation. In patients with LQTS/+VT and diQTP/+VT, transient accentuations of EMW negativity were observed at the time point closest to VT (2 days [1–7] to arrhythmia), regardless of whether measured before or after VT. Temporary EMW negativity accentuation was driven by foreshortening of the mechanical systole despite concurrent QT prolongation. EMW recovery after VT was similar for patients with or without beta-blocker therapy. Multiple logistic regression analysis identified EMW negativity and EMW dynamics (ΔEMW) as independent predictors of imminent VT in LQTS. An EMW of −75 ms and a ΔEMW of −39 ms were optimal cutoffs to predict emergent arrhythmic deterioration in the LQTS cohort. Conclusion Temporary accentuation of EMW negativity is a marker of impending VT in patients with LQTS and diQTP.
KW - Drug-induced QT prolongation
KW - Echocardiography
KW - Electromechanical window
KW - Long-QT syndrome
KW - Risk stratification
KW - Sudden cardiac death
U2 - 10.1016/j.hrthm.2026.01.013
DO - 10.1016/j.hrthm.2026.01.013
M3 - Article
SN - 1547-5271
VL - 23
SP - e636-e646
JO - Heart Rhythm
JF - Heart Rhythm
IS - 4
ER -